In contrast, immunotherapy has been shown to benefit prognosis and survival in NFE2L2-mutant NSCLC [22] Targeted therapy against NFE2L2 could be applied combinatorially with immunotherapy, and may show strong benefit, based on high cancer effect of the mutations and the potential of abrogation of mutant gain-of-function to reintroduce sensitivity to chemotherapy [46]. Here, NFE2L2 is linked to non-small cell lung carcinoma.